Adult obstructive sleep apnoea, otherwise known as Obstructive Sleep Apnea-Hypopnea (OSAH), is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing (SDB) and is characterized by recurrent episodes of upper airway collapse during sleep.
This report provides the current prevalent population for OSAH across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from our analysis team, several of the main symptoms and co-morbidities of OSAH have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for OSAH include:
• Obesity (higher BMI - markedly in males rather than females)
• Congestive heart failure (CHF) & left ventricular dysfunction (due to oxygen de-saturation)
• Stroke (in more severe stages)
• MI
• Hypertension
• Diabetes
• Insulin resistance
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
• Able to quantify patient populations in global OSAH market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of OSAH and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on OSAH prevalent population.
• Identify sub-populations within OSAH which require treatment.
• Gain an understanding of the specific markets that have the largest number of OSAH patients.
'
Table of Contents
• List of Tables and Figures
• Introduction
• Cause of the Disease
• Risk Factors & Prevention
• Diagnosis of the Disease
• Variation by Geography/Ethnicity
• Disease Prognosis & Clinical Course
• Key comorbid conditions/Features associated with the disease
• Methodology for quantification of patient numbers
• Top-line prevalence for Adult Obstructive Sleep Apnoea
• Features of Adult Obstructive Sleep Apnoea patients
o Diagnostic status
o Severity
• Mild OSAH
o BMI Status
o CVD Mortality Rate
o Diabetes
o e-LFCNB
o Hypertension
o Snoring
• Moderate OSAH
o BMI Status
o CVD Mortality Rate
o Diabetes
o e-LFCNB
o Hypertension
o Snoring
• Severe OSAH
o BMI Status
o CVD Mortality Rate
o Diabetes
o e-LFCNB
o Hypertension
o Snoring
o Stroke
• Abbreviations used in the report
• Other Black Swan Analysis Publications
• Black Swan Analysis Online Patient-Based Databases
• Patient-Based Offering
• Online Pricing Data and Platforms
• References
• Appendix
List of Tables
• OSAH Severity
• Prevalence of Adult Obstructive Sleep Apnoea, total (000s)
• Prevalence of Adult Obstructive Sleep Apnoea, males (000s)
• Prevalence of Adult Obstructive Sleep Apnoea, females (000s)
• Diagnostic status of OSAH patients, total (000s)
• Severity of OSAH in patients, total (000s)
• BMI status in Mild OSAH patients, total (000s)
• CVD mortality rate in Mild OSAH patients, total (000s)
• Diabetes in Mild OSAH patients, total (000s)
• e-LFCNB in Mild OSAH patients, total (000s)
• Hypertension in Mild OSAH patients, total (000s)
• Snoring in Mild OSAH patients, total (000s)
• BMI status in Moderate OSAH patients, total (000s)
• CVD mortality rate in Moderate OSAH patients, total (000s)
• Diabetes in Moderate OSAH patients, total (000s)
• e-LFCNB in Moderate OSAH patients, total (000s)
• Hypertension in Moderate OSAH patients, total (000s)
• Snoring in Moderate OSAH patients, total (000s)
• BMI status in Severe OSAH patients, total (000s)
• CVD mortality rate in Severe OSAH patients, total (000s)
• Diabetes in Severe OSAH patients, total (000s)
• e-LFCNB in Severe OSAH patients, total (000s)
• Hypertension in Severe OSAH patients, total (000s)
• Snoring in Severe OSAH patients, total (000s)
• Stroke in Severe OSAH patients, total (000s)
• Abbreviations and Acronyms used in the report
• USA Prevalence of OSAH by 5-yr age cohort, males (000s)
• USA Prevalence of OSAH by 5-yr age cohort, females (000s)
• France Prevalence of OSAH by 5-yr age cohort, males (000s)
• France Prevalence of OSAH by 5-yr age cohort, females (000s)
• Germany Prevalence of OSAH by 5-yr age cohort, males (000s)
• Germany Prevalence of OSAH by 5-yr age cohort, females (000s)
• Italy Prevalence of OSAH by 5-yr age cohort, males (000s)
• Italy Prevalence of OSAH by 5-yr age cohort, females (000s)
• Spain Prevalence of OSAH by 5-yr age cohort, males (000s)
• Spain Prevalence of OSAH by 5-yr age cohort, females (000s)
• UK Prevalence of OSAH by 5-yr age cohort, males (000s)
• UK Prevalence of OSAH by 5-yr age cohort, females (000s)
• Brazil Prevalence of OSAH by 5-yr age cohort, males (000s)
• Brazil Prevalence of OSAH by 5-yr age cohort, females (000s)
• Japan Prevalence of OSAH by 5-yr age cohort, males (000s)
• Japan Prevalence of OSAH by 5-yr age cohort, females (000s)
